AQR Arbitrage’s DA32 Life Science Tech Acquisition Corp. Class A Common Stock DALS Stock Holding History

AQR Arbitrage’s Portfolio DALS Stock Details DALS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-401,880	Closed	-$4.12M	–	938
2023 Q2	$4.12M	Buy	401,880 +124,552	+45%	+$1.27M	0.18%	151
2023 Q1	$2.81M	Hold	277,328	–	–	0.09%	267
2022 Q4	$2.75M	Buy	277,328 +20,000	+8%	+$197K	0.07%	348
2022 Q3	$2.49M	Hold	257,328	–	–	0.05%	435
2022 Q2	$2.49M	Buy	+257,328	New	+$2.5M	0.06%	404

AQR Arbitrage's DALS Position: Q3 2023 in Review

AQR Arbitrage sold out of DA32 Life Science Tech Acquisition Corp. Class A Common Stock (DALS) in Q3 2023, closing a stake of 401,880 shares — an estimated $4.12M sold.

AQR Arbitrage first reported a position in DALS in Q2 2022 and held it in 5 quarters. The position peaked at $4.12M in Q2 2023. 0 funds tracked by Wall St. Rank hold DALS as of Q3 2023.

AQR Arbitrage reported no remaining DA32 Life Science Tech Acquisition Corp. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
AQR Arbitrage sold 401,880 DA32 Life Science Tech Acquisition Corp. Class A Common Stock shares in Q3 2023, an estimated $4.12M.
AQR Arbitrage first reported a position in DA32 Life Science Tech Acquisition Corp. Class A Common Stock in Q2 2022 and held it in 5 quarters.
AQR Arbitrage's DA32 Life Science Tech Acquisition Corp. Class A Common Stock position peaked at $4.12M in Q2 2023.
0 funds tracked by Wall St. Rank held DA32 Life Science Tech Acquisition Corp. Class A Common Stock as of Q3 2023.

Based on AQR Arbitrage's 13F filing for Q3 2023, filed 14 Nov 2023.